Cryptosporidium spp. infections have a significant effect on both human and animal health globally. Cryptosporidiosis is one of the leading causes of diarrhoeal mortality in children under five. C. parvum infections in ruminants can result in economic losses for farmers. In the UK and EU there are currently no drugs approved for use against Cryptosporidium spp., while Nitazoxanide is currently the only FDA approved in the US for treatment of infection in humans. Development of anti-parasitic drugs for C. parvum has been, in part, slowed by the inability to readily co-culture C. parvum in vitro with monocultures for extended periods of time, with HCT-8 cells typically supporting C. parvum growth for only 72 hours. Fertilisation in HCT-8 culture is currently the rate limiting step. While other systems, such as organoids, facilitate oocyst formation they remain inefficient. Here, we show the COLO-680N cell line readily supports prolonged growth of C. parvum beyond 72 hours. Using techniques such as qPCR, manual counting and fluorescence microscopy to validate prolonged growth and life cycle stage development. We present imaging of discrete lifecycle stages of C. parvum growth, complemented by fold-change analysis of key mRNAs associated with different life cycle stages in vitro which are significantly expressed during certain time points post infection. We have also used the COLO-680N system to determine GC₅₀ concentrations of two key drugs: Paromomycin (9.72µM) and Nitazoxanide (15.4µM) for C. parvum. Furthermore, we have been able to cryopreserve C. parvum-infected COLO-680N cells, with renewed growth validated using EdU-labelling. This technology enabling straightforward cryopreservation of clinical strains and transgenic lines. Overall, we track C. parvum development in COLO-680N cells over time, screen inhibitory compounds using this system and demonstrate straight forward methods for cryopreservation of Cryptosporidium from culture.